AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor that targets acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1), with IC50 values of 0.058 µM, 0.082 µM, and 0.115 µM against hAChE, hBChE, and hBACE-1, respectively. It exhibits significant binding affinity with PAS-AChE, excellent blood-brain barrier permeability, potential disassembly of amyloid-beta (Abeta) aggregates, neuroprotective properties against Abeta-induced stress, and remarkable antioxidant capabilities [1].
